FLSM
THRX

Frazier Life Sciences Management’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Frazier Life Sciences Management’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,118,051
Closed -$8.58M – 55
2023
Q4 		$8.58M Sell
2,118,051
-130,143
-6% -$397K 0.46% 43
2023
Q3 		$6.05M Hold
2,248,194
– – 0.4% 41
2023
Q2 		$21M Hold
2,248,194
– – 1.25% 19
2023
Q1 		$20M Buy
2,248,194
+850,000
+61% +$8.34M 1.45% 18
2022
Q4 		$6.96M Buy
+1,398,194
New +$8.19M 0.43% 37

Frazier Life Sciences Management's THRX Position: Q1 2024 in Review

Frazier Life Sciences Management sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 2,118,051 shares — an estimated $8.58M sold.

Frazier Life Sciences Management first reported a position in THRX in Q4 2022 and held it in 5 quarters. The position peaked at $21M in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

  • Frazier Life Sciences Management reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Frazier Life Sciences Management sold 2,118,051 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $8.58M.
  • Frazier Life Sciences Management first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 5 quarters.
  • Frazier Life Sciences Management's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $21M in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Frazier Life Sciences Management's 13F filing for Q1 2024, filed 15 May 2024.